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treated with emergency surgery: a case report 
and literature review
Katsura Kakoki1, Yasuyoshi Miyata1*, Youhei Shida1, Tomoaki Hakariya1, Kosuke Takehara1, Seiya Izumida2, 
Motohiro Sekino3, Naoe Kinoshita4, Tsukasa Igawa1,5, Junya Fukuoka4 and Hideki Sakai1
Abstract 
Background: Pheochromocytoma is a neuroendocrine tumor that predominantly presents with hypertension, palpi-
tations, and tachycardia due to excessive catecholamine excretion. Although pheochromocytoma multisystem crisis 
(PMC) is relatively rare, urologists and clinicians should focus on early diagnosis as delay in initiating the appropriate 
treatment can lead to mortality
Case presentation: A 70-year-old man developed ileus after a few days of medication for hypertension. Computed 
tomography incidentally revealed a left adrenal mass. This finding together with his clinical course was compatible 
with pheochromocytoma. An α-blocker was administered immediately, and his blood pressure was well controlled. 
However, his general condition and laboratory data deteriorated rapidly, and the patient was diagnosed with PMC 
with lethal status. Thus, emergency adrenalectomy was performed without confirmation of catecholamine levels. 
From the resected specimen, his tumor was judged as pheochromocytoma. On immunohistochemical analysis, the 
proliferation index evaluated by Ki-67 staining was 9.7 %. This case report was approved by the Human Ethics Review 
Committee of the Nagasaki University Hospital.
Conclusion: The present case of PMC was successfully treated with emergency surgery. The benign pheochromo-
cytoma also presented with high cell proliferation potential, which may be a cause of the extreme aggressiveness of 
PMC.
Keywords: Pheochromocytoma multisystem crisis, Treatment strategy, Outcome, Cell proliferation, Malignant 
pheochromocytoma
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Background
Pheochromocytoma is a relatively rare neuroendocrine 
tumor that predominantly presents with proximal or 
sustained hypertension, palpitations, tachycardia, and 
sweating due to excessive catecholamine release. These 
symptoms are often severe, and some patients can enter 
‘pheochromocytoma crisis’ [1, 2]. Patients judged to be 
in pheochromocytoma crisis require treatment with anti-
hypertensive drugs and transfusion. The standard treat-
ment for ‘non-crisis’ pheochromocytoma is generally 
preoperative preparation with an α-blocker and surgical 
resection [1].
Pheochromocytoma multisystem crisis (PMC) is a fatal 
condition characterized by multiple organ failure, severe 
blood pressure variability, high fever, and encephalopathy 
[2]. Importantly, PMC is not synonymous with malignant 
hypertension caused by the massive release of catecho-
lamine’s from the pheochromocytoma. Indeed, several 
patients with PMC were reported to be normotensive or 
hypotensive [3, 4]. In addition, the symptoms and patho-
logical conditions of PMC vary greatly. Abdominal pain, 
nausea, and dyspnea are common, while anemia, back 
pain, night sweat, and acidosis have also been reported 
[5]. Therefore, many patients with PMC are unrecognized 
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at diagnosis [5]. The treatment strategy for patients with 
PMC requires particular attention, as delayed therapy 
can lead to severe sequelae or mortality.
Detailed information on the diagnosis and treatment 
of PMC is important for physicians. In addition, under-
standing the pathological characteristics of PMC is 
essential for developing diagnostic tools and treatment 
strategies. Unfortunately, there are few reports on the 
molecular biological findings or pathological character-
istics in PMC patients [6]. Herein, we report a case of 
a patient with PMC who was successfully treated with 
emergency surgery. We also provide a literature review of 
the symptoms, data, treatments, and outcome of patients 
with PMC, as well as the relationship between cell prolif-
eration and malignant potential in pheochromocytoma. 
The present case report presents new and important 
information for future studies on PMC. The authors 
obtained approval from the Human Ethics Review Com-
mittee of Nagasaki University Hospital for the publica-
tion of this report.
Case presentation
A 70-year-old man was admitted to our hospital for 
ileus and uncontrollable high blood pressure. His sys-
tolic blood pressure exceeded 160  mmHg, and oral 
diltiazem and amilodipin were initiated 5  days before 
the onset of ileus. Computed tomography showed a left 
adrenal mass and ileus (Fig.  1). His consciousness level 
was low with incoherent speech. His body temperature 
was 37.4  °C, pulse rate was 126  bpm, blood pressure 
was 210/146  mmHg, and SpO2 was 98  % on room air. 
He appeared to be sweating profusely, with cold moist 
peripheries. Electrocardiogram showed sinus rhythm 
tachycardia and short PQ, high voltage, mitral P, and 
negative T on V4–6. Abdominal radiography showed 
large intestine expansion due to gas. Initial labora-
tory data showed low thrombocyte count (74,000/μL), 
normal white blood cell count (6000/μL), high levels of 
hemoglobin (16.3  g/dL), C-reactive protein (9.30  mg/
dL), serum glucose (201  mg/dL), and blood urea nitro-
gen (48  mg/dL), and normal level of serum creatinine 
(1.05 mg/dL). Amino-terminal pro-brain natriuretic pep-
tide was extremely high at 13,938.0 ng/mL.
We suspected pheochromocytoma on the basis of his 
computed tomography findings and clinical features. 
Doxazosin (2  mg/day orally), nicardipine (1.5  μg/kg/h 
i.v.), and landiolol (200  mg/day i.v.) were administered 
for blood pressure control. Because of the high fever, we 
suspected necrotizing enteritis due to ileus. Therefore, 
intravenous antibiotics were administered. Moreover, 
creatinine kinase and lactose dehydrogenase increased 
rapidly to 7066 and 609 IU/L, respectively. At that time, 
his body temperature was 40.1  °C. His respiratory state 
was aggravated after 3  days in the hospital, and oxygen 
was started. Laboratory tests showed that renal and liver 
functions were deteriorating. Five days after hospitaliza-
tion, tracheal intubation was performed in the intensive 
care unit. Artificial ventilation and continuous hemodia-
filtration were started.
The patient was diagnosed with PMC on the basis of 
the clinical course and radiological findings, without 
considering serum catecholamine levels. We performed 
emergency left adrenalectomy despite his critical con-
dition, as he showed poor control and was refractory to 
medical treatment. Intraoperatively, the anesthesiologist 
used several types of antihypertensive drugs including 
doxazosin, landiolol hydrochloride, and diltiazem as nec-
essary. Although temporary blood pressure was reduced 
to 80/46  mmHg after removal of the adrenal gland, the 
patient’s vital signs stabilized quickly after catecholamine 
infusion.
Postoperatively, the patient’s blood catecholamine lev-
els intraoperatively were: epinephrine 10,351 (normal 
range ≤100 ng/mL), norepinephrine 27,654 ng/mL (nor-
mal range 100–450  ng/mL), and dopamine 209,500  ng/
mL (normal range ≤20  ng/mL). The patient recovered 
rapidly postoperatively. One day postoperatively, his 
body temperature normalized. Furthermore, lactose 
dehydrogenase, creatinine kinase, liver function, res-
piratory status, and consciousness began to improve. He 
was weaned from ventilatory support at 2  days postop-
eratively, and from continuous hemodiafiltration and cat-
echolamine administration at 3 days postoperatively. He 
was discharged 37  days postoperatively. Various imag-
ing examinations including computed tomography and 
magnetic resonance imaging were performed during 
Fig. 1 Abdominal computed tomography revealed a large left adre-
nal mass with heterogeneous enhancement and extended intensity 
compatible with ileus
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hospitalization to reconfirm the absence of metastatic 
mass. He has had no tumor recurrence or metastasis for 
2 years.
The resected tumor was 12 ×  11 ×  8  cm in size and 
weighed 530  g, with prominent central necrosis and 
internal bleeding (Fig.  2). Histologically, the tumor had 
a capsule and was comprised of basophilic granular cells 
with polygonal features (Fig. 3). On immunohistochem-
istry, the specimen stained positive for chromogranin A, 
NCAM, and S100. Therefore, the tumor was identified as 
a pheochromocytoma. The cell proliferation index meas-
ured using an anti-Ki-67 antibody was 9.7 % (Fig. 4).
Discussion
The incidence of pheochromocytoma is approximately 
0.1 % in the hypertensive population [7]. Pheochromocy-
toma typically arises from the adrenal medulla, although 
may develop in chromaffin cells in or around sympa-
thetic ganglia [8]. The standard treatment for sympto-
matic pheochromocytoma is generally surgical resection. 
PMC is a more severe and potentially lethal condition of 
pheochromocytoma, and represents an endocrinological 
emergency [9]. Therefore, clinicians should have detailed 
information regarding the symptoms, diagnosis, and 
treatment of PMC, despite its rarity.
Several previous reports have stressed the importance 
of emergency treatment for PMC to avoid death [2, 
6]. Indeed, all European cases of PMC without surgical 
resection (5/12, 41.7  %) died despite conservative treat-
ment (Table 1). The results of physical examination and 
hormonal studies in previous PMC cases are shown in 
Table  1. Although extremely high blood pressure and 
fever are characteristics of PMC, two patients had no 
high-grade fever. Other signs and symptoms of PMC 
have been reported [5]. Therefore, accurate diagnosis on 
the basis of vital signs, symptoms, and physical examina-
tion can be difficult.
Our patient presented with hypertension and ileus 
at onset, while subsequent computed tomography per-
formed to examine the ileus revealed a left adrenal tumor. 
On admission, the patient did not present with high 
fever but showed a slight disturbance of consciousness 
and extremely high blood pressure. Despite blood pres-
sure control with α1-blocker treatment after hospitaliza-
tion, his body temperature increased and consciousness 
worsened. Moreover, liver dysfunction and respiratory 
distress developed. Thus, his symptoms met the diag-
nostic criteria of PMC. On the basis of these findings, 
we opted for emergency surgery before confirmation of 
blood catecholamine levels and Methoxy-Isobutyl-Isoni-
trile (MIBI) scintigraphy. His condition improved dra-
matically after surgery. He was weaned from continuous 
hemodiafiltration and respiration, catecholamine admin-
istration, and intubation at 4 days postoperatively.
Our case provides further support that surgical resection 
is important for preventing mortality in patients with PMC. 
Nevertheless, the appropriate timing of surgery remains 
unclear. As shown in Table 1, surgery on the day following 
admission may not be associated with outcome [2, 10, 11]. 
Fig. 2 Resected specimen showing a tumor measuring 14 cm in 
diameter. There was hemorrhage and necrosis within the tumor
Fig. 3 Hematoxylin-eosin staining (magnification: ×40)
Fig. 4 Ki-67 staining. The distribution of Ki-67-stained cells was non-
specific (magnification: ×200)
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In addition, other vital signs and clinicopathological features 
do not appear to be associated with outcome [2, 5, 6, 9–14]. 
Thus, in addition to the difficulty in diagnosis, the optimal 
treatment strategies for patients with PMC remain unclear.
The proliferation index evaluated by Ki-67 is commonly 
used to assess the cell-cycle. A number of case series have 
reported a PI measured by Ki-67 staining of less than 1 % 
in benign pheochromocytoma [15, 16] (Table 2). By con-
trast, our case of benign pheochromocytoma showed an 
extremely high level of cell proliferation potential, with 
a PI of 9.7  %. The relationships between cell prolifera-
tion and pathological characteristics including hormone 
secretion, tumor size, and symptoms in benign pheo-
chromocytoma are not fully understood, although PI 
was reported to be significantly associated with capsule 
invasion of pheochromocytoma [24]. The relationship 
between the aggressiveness of PMC and cell proliferation 
is unknown, as this is the first report on cell proliferation 
in PMC. Speculatively, the high proliferative potential 
despite benign tumor status may be a characteristic of 
PMC that contributes to its aggressive characteristics and 
severe symptoms in patients.
PI is also a useful marker for distinguishing benign from 
malignant pheochromocytoma [16–19]. We identified 
nine studies in PubMed describing a PI cut-off in adre-
nal malignant pheochromocytoma tissues; the suggested 
cut-offs for predicting malignant behavior are shown in 
Table  2. The PI in the present case was relatively higher 
Table 1 Characteristics, physical conditions, treatments, and outcomes of patients with pheochromocytoma multisystem 
crisis
M male, F female, S/DBP systolic/diastolic blood pressure, BT body temperature, Ad adrenalin, NAd noradrenalin, Dopa dopamine, Ref reference number
a 24 h urine correction
b Operation day following admission




BT (°C) Size  
(cm)




F 53 210/110 40 6.3 101.1 103.5 – Not performed Died 1988 [2]
F 62 285/140 40.5 10 96.0 14.8 – Emergency Survived 1988 [22]
F 50 200/90 40 7 43.3 23.4 – 7 Survived 1988 [2]
F 65 120/80 39.5 4 – – – >21 Survived 1993 [10]
M 31 164/40 41.0 – 10a 6.7a 1.3a 36 Survived 1997 [11]
F 50 160/100 41.5 – – – – Not performed Died 2002 [12]
F 41 190/130 41.0 – – – – – Survived 2006 [9]
F 26 160/110 – 4.5 – – – Not performed Died 2008 [6]
M 39 240/140 – 5.5 41.0 49.6 – Emergency Survived 2008 [6]
F 52 300/200 39.9 10 – – – Not performed Died 2010 [13]
F 52 162/104 35.8 – 103.5 53.9 53.1 – Survived 2010 [5]
M 27 160/120 – 5 – – – Not performed Died 2012 [14]
M 70 210/146 40.1 5 1047.5 61.5 103.5 5 Survived Present
Table 2 Mean proliferation indexes of benign and malignant adrenal pheochromocytoma
PI proliferation index
a Cut-off of PI (%) between benign and malignant pheochromocytoma
b Including extra-adrenal tumors
c Patients without metastasis at diagnosis
Benign
 N 23b 16 93 21 20 – 41 44 14
 PI (%) 1 0.75 0.21 0.9 <1 – 0.8 <1 2.2
Malignant
 N 10 15 36 4 3c 43 5 11 7
 PI (%) 5 13.9 3.0 4.3 <1 7.8 1.4 – 14.1
 Cut-offa >3 ≥3 >2.5 – – >5 >2 >5 –
Year 1998 2000 2000 2001 2003 2004 2008 2010 2012
Reference [17] [18] [19] [20] [15] [21] [22] [16] [23]
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than the mean PI in malignant pheochromocytoma, indi-
cating malignant and metastatic potential. However, no 
recurrence or metastatic mass was detected at 2  years 
postoperatively. Nevertheless, follow-up with imaging and 
hormonal studies are required as a part of the pheochro-
mocytoma can recur in various organ types [25].
Conclusions
We report a case of rapidly progressing and life-threat-
ening PMC. Although it is generally difficult to decide on 
the surgical strategy for patients with PMC, emergency 
surgery is important for achieving a favorable outcome. 
Therefore, urologists and clinicians should be aware of 
this rare life-threatening condition. In addition, we spec-
ulate that the aggressive characteristics of PMC may be 
due to a high proliferative potential. Additional studies 
examining the pathological characteristics of the disease 
at the molecular level are required to determine the bio-
logical characteristics of PMC and to develop strategies 
for diagnosis and treatment.
Consent
Written informed consent was obtained from the patient 
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